Related Experiment Videos
Target Perturbation of Genetically Proxied Antidiabetic Drug Targets and Pneumonia Risk: A Mendelian Randomization
Siyi Lin1, Hongxia Xu2, Jingyan Xia3
1Department of Infectious Diseases, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Current Topics in Medicinal Chemistry
|June 2, 2026
Summary
This study investigated the causal link between Type 2 Diabetes Mellitus (T2DM) medications and pneumonia risk using Mendelian Randomization. Certain antidiabetic drug targets show associations with pneumonia, offering new research directions.
Area of Science:
- Genetics
- Epidemiology
- Pharmacology
Background:
- Type 2 Diabetes Mellitus (T2DM) and its treatments are suspected to influence pneumonia incidence and mortality.
- The causal relationship between T2DM, antidiabetic medications, and pneumonia remains unclear.
Purpose of the Study:
- To evaluate the potential causal relationships between T2DM, specific antidiabetic drug targets, and pneumonia risk.
- To utilize Mendelian Randomization (MR) to assess these genetic associations.
Main Methods:
- Two-sample MR analyses were performed using genetic instruments for T2DM and six antidiabetic drug targets (PPARG, GIPR, GLP1R, INSR, ABCC8, KCNJ11).
- Data from FinnGen, GWAS Catalog, and other consortia were used for discovery and validation cohorts, with meta-analysis for integration.
- Exploratory Summary-data-based Mendelian Randomization (SMR) and sensitivity analyses were conducted.
Main Results:
- Strong associations were found between ABCC8/KCNJ11 and cytomegaloviral pneumonitis, and between GIPR and overall pneumonia risk.
- Nominal associations were observed for several drug targets with various pneumonia subtypes, though some had limited statistical power.
- Exploratory SMR analysis indicated potential links between ABCC8, GIPR, and pneumonia risk.
Conclusions:
- Genetically proxied antidiabetic drug targets demonstrate associations with pneumonia risk, generating hypotheses for further research.
- Findings suggest potential mechanisms linking T2DM pharmacotherapy to pneumonia.
- Larger studies are needed to validate these findings, especially for rare pneumonia subtypes.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...